Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period;...
According to Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period; net loss attributable to shareholders of listed companies was 294 million yuan, narrowing year-on-year losses; net losses attributable to shareholders of listed companies were deducted from non-recurring profit and loss of 325 million yuan, narrowing the year-on-year loss; basic loss per share was 2.97 yuan/share.
During the reporting period, in order to enhance the company's core competitiveness, continuously strengthen R&D team building, and continue to advance the progress of a number of innovative drug projects in different clinical trial research stages; at the same time, the company promoted commercialization preparations such as commercialization team building and formulating a marketing strategy system based on the progress of new drug development and the marketing review process for deuterium enzalutamide softgels (project number: HC-1119); the company has not yet obtained commercial sales approval and no operating income; the company has not yet achieved profit.